Contested Ground

Contested Ground : Public Purpose and Private Interest in the Regulation of Prescription Drugs

Edited by 

List price: US$42.51

Currently unavailable

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks


This book applies social science to the analysis of prescriptive drug policy. It identifies key policy issues in the public debate on prescription drugs and establishes an analytical framework for regulatory policy in this area. It describes the social and cultural context of prescription drugs as well as the pharmaceutical market and its distinctive industrial structure. Written by a range of international experts working at trhe interface between the social sciences, pharmacy, medicine, and public policy They raise important social, ethical and policy questions that cut across conventional disciplinary more

Product details

  • Hardback | 274 pages
  • 164.6 x 243.6 x 25.1mm | 641.97g
  • Oxford University Press Inc
  • New York, United States
  • English
  • line figures and tables
  • 0195091205
  • 9780195091205

Table of contents

Introduction: Medicines in a Post-Modern World; Part I: The Social and Cultural Context; 1. The Pharmakon Phenomenon: Cultural Conceptions of Drugs and Drug Use; 2. Medicalization and the Pharmacological Treatment of Blood Pressure; 3. The Mass Media and the Benzodiazepine Controversy; 4. Adverse Reactions, Social Responses: A Tale of Two Asthma Mortality Epidemics; 5. The Consumer Movement: From Single-Issue Campaigns to Long-Term Reform; Part II: The Product Cycle; 6. Market and Industrial Structure; 7. Pharmaceutical Innovation in a Changing Environment; 8. Prices for Prescription Drugs: The Role of Market Forces and Government Regulation; 9. The Professional and Corporate Context: Trends in the United States; 10. Pharmacy in the Western World Health Care Systems; Part III: The Regulatory Framework: International Innovation; 11. Pharmaceutical Policy and Regulation: Setting the Pace in the European Community; 12. The Liberalization of Access to Medication in the United States and Europe; 13. Developments in Economic Evaluation: The Subsidization of Pharmaceuticals; 14. The Self-Regulation of Pharmaceutical Marketing: Initiatives for Reform; 15. New Approaches to Influencing Physicians' Drug Choices: The Practice-Based Strategy; 16. Technology and Social Choice: Policy Scenarios for Prescription Drugsshow more